Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00344227 · ClinicalTrials.gov registry record · Phase 2
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
A Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00344227 is a Phase 2 study of Neovascular Age-related Macular Degeneration that has completed, run by University of Miami. The registered enrollment target is 40 participants, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00344227, a Phase 2 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging. OCT was then used to determine the need for retreatment after 3 monthly injections of Lucentis. Patients would be followed for 2 years.
Conditions Studied
Interventions
- DRUG Lucentis (Ranibizumab)
Study Locations (1)
Florida
- Bascom Palmer Eye Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00344227
The ClinicalTrials.gov registry entry for NCT00344227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (90% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Lucentis (Ranibizumab) is the first listed.
NCT00344227 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00344227 about?
NCT00344227 is a clinical study titled "Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)". The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging. OCT was then used to determine the need for retreatment after 3 monthly injections of Lucentis. Patients wo...
What is the current status of trial NCT00344227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-08. Estimated completion is 2007-04.
What conditions does trial NCT00344227 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT00344227?
The interventions under investigation include: Lucentis (Ranibizumab) (DRUG).
Who is sponsoring clinical trial NCT00344227?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00344227 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
COMPLETED · Phase 2
-
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.